Strona główna・Stock List・United Therapeutics Corp

United Therapeutics Corp

Open

SectorHealthcare

509.07 -0.88

Buy Sell

Overview

Share price change

24h

Current

Min

503.46

Max

527.86

Key metrics
By Trading Economics
Income	58M 333M
Sales	1.8M 783M
P/E Sector Avg	18.971 57.002
EPS	7.27
Profit margin	42.512
Employees	1,400
EBITDA	32M 376M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+27.09% upside

Dividends
By Acuity
Next Earnings	28 paź 2026

Market Stats
By TradingEconomics
Market Cap	-3B 23B
Previous open	509.95
Previous close	509.07

News Sentiment

By Acuity

43%

57%

115 / 340 Ranking in Healthcare

United Therapeutics Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 sie 2026, 23:02 UTC

United Therapeutics Corp is trading lower in after-market hours, continuing a trend of three consecutive daily declines without any specific news driving the movement.

10 sie 2026, 20:06 UTC

United Therapeutics Corp shares are lower during Monday's session, with no specific news identified to explain the decline amid broader market volatility.

7 sie 2026, 19:51 UTC

Social Media

News

United Therapeutics Corp shares are higher, driven by positive sentiment from significant insider transactions and strong investor interest amid a rising Biotechnology sector.

6 sie 2026, 23:01 UTC

United Therapeutics Corp. shares are higher in after-market trading, continuing a steady increase since Thursday's close and remaining above the 20-day moving average.

5 sie 2026, 20:02 UTC

News

Social Media

United Therapeutics reported second-quarter revenues of $783.3 million, missing estimates of $805.6 million, while EPS of $7.27 exceeded expectations by $0.18.

4 sie 2026, 23:51 UTC

Shares of United Therapeutics Corp. are lower in after-market hours, remaining below the 20-day moving average and near the lower end of their one-month trading range.

3 sie 2026, 19:16 UTC

Shares of United Therapeutics Corp are lower today, trading near the lower end of their one-month range amid a broader market rally in other sectors.

30 lip 2026, 14:36 UTC

Event

United Therapeutics shares are higher following the publication of full ADVANCE OUTCOMES study results in The Lancet, pending FDA approval for ralinepag.

29 lip 2026, 20:51 UTC

Event

United Therapeutics shares are higher in after-market trading following The Lancet's publication of results from the ADVANCE OUTCOMES study on Ralinepag for PAH.

28 lip 2026, 18:21 UTC

United Therapeutics Corp. shares are lower today, continuing a decline since Monday's close amid broader market trends and three consecutive sessions of lower finishes.

24 lip 2026, 16:36 UTC

News

Social Media

United Therapeutics appointed Victor Dzau to its Board of Directors, enhancing its strategic direction. Shares are modestly higher since Thursday's close.

22 lip 2026, 19:41 UTC

News

United Therapeutics filed an $833.4 million shelf registration for 1.5 million shares, contributing to downward pressure on shares amid broader market movements.

21 lip 2026, 16:56 UTC

United Therapeutics Corp is seeing modest gains today, with positive sentiment from Asian markets contributing to overall investor optimism. No specific news was identified.

Peer Comparison

Price change

United Therapeutics Corp Forecast

Price Target

By TipRanks

27.09% upside

12 Months Forecast

Average 655.13 USD 27.09%

High 714 USD

Low 515 USD

Based on 9 Wall Street analysts offering 12 month price targets forUnited Therapeutics Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to United Therapeutics Corp - Dist in the past 3 months.

Sentiment

By Acuity

115 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.